array(1) { [0]=> object(Apache_Solr_Document)#24 (3) { ["_documentBoost":protected]=> bool(false) ["_fields":protected]=> array(6) { ["content_id"]=> array(1) { [0]=> string(14) "DIRECTORY_9845" } ["content_title"]=> array(1) { [0]=> string(14) "MARCO GALLUZZO" } ["description"]=> array(1) { [0]=> string(67318) " a:69:{i:0;a:14:{s:9:"citazione";s:263:"Gisondi, P., Talamonti, M., Chiricozzi, A., Piaserico, S., Amerio, P., Balato, A., et al. (2021). Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. DERMATOLOGY AND THERAPY, 11(1), 235-252.";s:4:"data";s:4:"2021";s:2:"id";s:20:"PUBBLICAZIONE_410001";s:6:"handle";s:11:"2108/265356";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:123:"Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations";s:9:"metadata6";s:500:"Gisondi, P; Talamonti, M; Chiricozzi, A; Piaserico, S; Amerio, P; Balato, A; Bardazzi, F; Calzavara Pinton, P; Campanati, A; Cattaneo, A; Dapavo, P; De Simone, C; Dini, V; Fargnoli, MC; Flori, ML; Galluzzo, M; Guarneri, C; Lasagni, C; Loconsole, F; Lo Schiavo, A; Malagoli, P; Malara, G; Mercuri, SR; Musumeci, ML; Naldi, L; Papini, M; Parodi, A; Potenza, C; Prignano, F; Rongioletti, F; Stingeni, L; Tiberio, R; Venturini, M; Bianchi, L; Costanzo, A; Cusano, F; Girolomoni, G; Offidani, AM; Peris, K";s:9:"metadata7";s:26:"10.1007/s13555-020-00475-8";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:1;a:14:{s:9:"citazione";s:356:"Morelli, M., Galluzzo, M., Madonna, S., Scarponi, C., Scaglione, G.L., Galluccio, T., et al. (2021). HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. EXPERT OPINION ON BIOLOGICAL THERAPY, 21(2), 259-270 [10.1080/14712598.2021.1862082].";s:4:"data";s:4:"2021";s:2:"id";s:20:"PUBBLICAZIONE_404527";s:6:"handle";s:11:"2108/260562";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:168:"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis";s:9:"metadata6";s:157:"Morelli, M; Galluzzo, M; Madonna, S; Scarponi, C; Scaglione, GL; Galluccio, T; Andreani, M; Pallotta, S; Girolomoni, G; Bianchi, L; Talamonti, M; Albanesi, C";s:9:"metadata7";s:29:"10.1080/14712598.2021.1862082";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:2;a:14:{s:9:"citazione";s:360:"Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., et al. (2021). Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study. EXPERT OPINION ON BIOLOGICAL THERAPY, 21(2), 271-277 [10.1080/14712598.2021.1853698].";s:4:"data";s:4:"2021";s:2:"id";s:20:"PUBBLICAZIONE_403906";s:6:"handle";s:11:"2108/260000";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:170:"Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study";s:9:"metadata6";s:459:"Talamonti, M; Galluzzo, M; Chiricozzi, A; Quaglino, P; Fabbrocini, G; Gisondi, P; Marzano, AV; Potenza, C; Conti, A; Parodi, A; Piaserico, S; Bardazzi, F; Argenziano, G; Rongioletti, F; Stingeni, L; Micali, G; Loconsole, F; Rossi, MT; Bongiorno, MR; Feliciani, C; Rubegni, P; Amerio, P; Fargnoli, MC; Pigatto, P; Savoia, P; Nisticò, SP; Giustini, S; Carugno, A; Cannavo', SP; Rech, G; Prignano, F; Offidani, A; Lombardo, M; Zalaudek, I; Bianchi, L; Peris, K";s:9:"metadata7";s:29:"10.1080/14712598.2021.1853698";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:3;a:14:{s:9:"citazione";s:291:"Galluzzo, M., Talamonti, M., Manfreda, V., Silvaggio, D., Tartaglia, C., Roberto, D., et al. (2020). Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. EXPERT OPINION ON BIOLOGICAL THERAPY [10.1080/14712598.2021.1849131].";s:4:"data";s:10:"2020-11-27";s:2:"id";s:20:"PUBBLICAZIONE_403901";s:6:"handle";s:11:"2108/259996";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:119:"Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies";s:9:"metadata6";s:103:"Galluzzo, M; Talamonti, M; Manfreda, V; Silvaggio, D; Tartaglia, C; Roberto, D; Campione, E; Bianchi, L";s:9:"metadata7";s:29:"10.1080/14712598.2021.1849131";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:4;a:14:{s:9:"citazione";s:278:"Talamonti, M., & Galluzzo, M. (2020). Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information. ANNALS OF TRANSLATIONAL MEDICINE, 8(15), 971-971.";s:4:"data";s:7:"2020-08";s:2:"id";s:20:"PUBBLICAZIONE_402169";s:6:"handle";s:11:"2108/258408";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:189:"Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information";s:9:"metadata6";s:25:"Talamonti, M; Galluzzo, M";s:9:"metadata7";s:23:"10.21037/atm.2020.04.05";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:5;a:14:{s:9:"citazione";s:266:"Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., et al. (2020). Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY.";s:4:"data";s:10:"2020-07-31";s:2:"id";s:20:"PUBBLICAZIONE_398530";s:6:"handle";s:11:"2108/255090";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:98:"Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy";s:9:"metadata6";s:469:"Talamonti, M; Galluzzo, M; Chiricozzi, A; Quaglino, P; Fabbrocini, G; Gisondi, P; Marzano, Av; Potenza, C; Conti, A; Parodi, A; Belloni Fortina, A; Bardazzi, F; Argenziano, G; Rongioletti, F; Stingeni, L; Micali, G; Loconsole, F; Venturini, M; Bongiorno, Mr; Feliciani, C; Rubegni, P; Amerio, P; Fargnoli, Mc; Pigatto, P; Savoia, P; Nisticò, Sp; Giustini, S; Carugno, A; Cannavò, Sp; Rech, G; Prignano, F; Offidani, A; Lombardo, M; Zalaudek, I; Bianchi, L; Peris, K";s:9:"metadata7";s:17:"10.1111/jdv.16841";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:6;a:14:{s:9:"citazione";s:243:"Galluzzo, M., Tofani, L., Lombardo, P., Petruzzellis, A., Silvaggio, D., Egan, C.g., et al. (2020). Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. JOURNAL OF CLINICAL MEDICINE, 9(7), 2170.";s:4:"data";s:10:"2020-07-09";s:2:"id";s:20:"PUBBLICAZIONE_398536";s:6:"handle";s:11:"2108/255096";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:100:"Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study";s:9:"metadata6";s:102:"Galluzzo, M; Tofani, L; Lombardo, P; Petruzzellis, A; Silvaggio, D; Egan, Cg; Bianchi, L; Talamonti, M";s:9:"metadata7";s:18:"10.3390/jcm9072170";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:7;a:14:{s:9:"citazione";s:223:"Talamonti, M., Tofani, L., Bianchi, L., & Galluzzo, M. (2020). Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?. ARCHIVES OF DERMATOLOGICAL RESEARCH.";s:4:"data";s:10:"2020-07-09";s:2:"id";s:20:"PUBBLICAZIONE_398538";s:6:"handle";s:11:"2108/255098";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:122:"Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?";s:9:"metadata6";s:48:"Talamonti, M; Tofani, L; Bianchi, L; Galluzzo, M";s:9:"metadata7";s:26:"10.1007/s00403-020-02103-z";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:8;a:14:{s:9:"citazione";s:251:"Mazzilli, S., Lanna, C., Chiaramonte, C., Cesaroni, G.M., Zangrilli, A., Palumbo, V., et al. (2020). Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. JOURNAL OF DERMATOLOGY.";s:4:"data";s:10:"2020-04-01";s:2:"id";s:20:"PUBBLICAZIONE_385616";s:6:"handle";s:11:"2108/243819";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:125:"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers";s:9:"metadata6";s:175:"Mazzilli, S; Lanna, C; Chiaramonte, C; Cesaroni, GM; Zangrilli, A; Palumbo, V; Cosio, T; Dattola, A; Gaziano, R; Galluzzo, M; Chimenti, MS; Gisondi, P; Bianchi, L; Campione, E";s:9:"metadata7";s:23:"10.1111/1346-8138.15293";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:9;a:14:{s:9:"citazione";s:346:"Caldarola, G., Pirro, F., Di Stefani, A., Talamonti, M., Galluzzo, M., D'Adamio, S., et al. (2020). Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(6), 665-672 [10.1080/14712598.2020.1727439].";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_370808";s:6:"handle";s:11:"2108/230862";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:159:"Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature";s:9:"metadata6";s:178:"Caldarola, G; Pirro, F; Di Stefani, A; Talamonti, M; Galluzzo, M; D'Adamio, S; Magnano, M; Bernardini, N; Malagoli, P; Bardazzi, F; Potenza, C; Bianchi, L; Peris, K; De Simone, C";s:9:"metadata7";s:29:"10.1080/14712598.2020.1727439";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:10;a:14:{s:9:"citazione";s:253:"Campione, E., Lanna, C., Diluvio, L., Cannizzaro, M.V., Grelli, S., Galluzzo, M., et al. (2020). Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. CELL CYCLE, 19(3), 257-267 [10.1080/15384101.2019.1707455].";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_379009";s:6:"handle";s:11:"2108/238216";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore BIO/10";s:9:"metadata4";N;s:9:"metadata5";s:95:"Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo";s:9:"metadata6";s:193:"Campione, E; Lanna, C; Diluvio, L; Cannizzaro, MV; Grelli, S; Galluzzo, M; Talamonti, M; Annicchiarico-Petruzzelli, M; Mancini, M; Melino, G; Candi, E; Schiavone, G; Wang, Y; Shi, Y; Bianchi, L";s:9:"metadata7";s:29:"10.1080/15384101.2019.1707455";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:11;a:14:{s:9:"citazione";s:236:"D'Adamio, S., Massaro, A., Biocca, S., Bianchi, L., Talamonti, M., & Galluzzo, M. (2020). A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 45(6), 809-810.";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_402165";s:6:"handle";s:11:"2108/258404";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:90:"A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab";s:9:"metadata6";s:73:"D'Adamio, S; Massaro, A; Biocca, S; Bianchi, L; Talamonti, M; Galluzzo, M";s:9:"metadata7";s:17:"10.1111/ced.14276";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:12;a:14:{s:9:"citazione";s:348:"Galluzzo, M., D'Adamio, S., Silvaggio, D., Lombardo, P., Bianchi, L., & Talamonti, M. (2020). In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(2), 173-182 [10.1080/14712598.2020.1708897].";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_375833";s:6:"handle";s:11:"2108/235131";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:167:"In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis";s:9:"metadata6";s:77:"Galluzzo, M; D'Adamio, S; Silvaggio, D; Lombardo, P; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/14712598.2020.1708897";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:13;a:14:{s:9:"citazione";s:277:"Galluzzo, M., D'Adamio, S., Silvaggio, D., Lombardo, P., Massaro, A., Egan, C.G., et al. (2020). Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(1), 95-104 [10.1080/14712598.2020.1684472].";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_359680";s:6:"handle";s:11:"2108/221583";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:94:"Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience";s:9:"metadata6";s:99:"Galluzzo, M; D'Adamio, S; Silvaggio, D; Lombardo, P; Massaro, A; Egan, CG; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/14712598.2020.1684472";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:14;a:14:{s:9:"citazione";s:295:"Galluzzo, M., Tofani, L., Bianchi, L., & Talamonti, M. (2020). Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(8), 829-830.";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_402167";s:6:"handle";s:11:"2108/258406";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:177:"Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era";s:9:"metadata6";s:48:"Galluzzo, M; Tofani, L; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/14712598.2020.1779217";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:15;a:14:{s:9:"citazione";s:416:"van Vugt, L.J., van den Reek, J., Meulewaeter, E., Hakobjan, M., Heddes, N., Traks, T., et al. (2020). Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 34(1), 112-118.";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_382046";s:6:"handle";s:11:"2108/240787";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:232:"Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts";s:9:"metadata6";s:159:"van Vugt, LJ; van den Reek, JMPA; Meulewaeter, E; Hakobjan, M; Heddes, N; Traks, T; Kingo, K; Galluzzo, M; Talamonti, M; Lambert, J; Coenen, MJH; de Jong, EMGJ";s:9:"metadata7";s:17:"10.1111/jdv.15787";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:16;a:14:{s:9:"citazione";s:257:"D'Adamio, S., Silvaggio, D., Massaro, A., Lombardo, P., Bianchi, L., Talamonti, M., et al. (2019). Pharmacotherapeutic management of psoriasis in adolescents and children. EXPERT OPINION ON PHARMACOTHERAPY, 20(14), 1777-1785 [10.1080/14656566.2019.1636032].";s:4:"data";s:10:"2019-07-04";s:2:"id";s:20:"PUBBLICAZIONE_354526";s:6:"handle";s:11:"2108/217203";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:71:"Pharmacotherapeutic management of psoriasis in adolescents and children";s:9:"metadata6";s:89:"D'Adamio, S; Silvaggio, D; Massaro, A; Lombardo, P; Bianchi, L; Talamonti, M; Galluzzo, M";s:9:"metadata7";s:29:"10.1080/14656566.2019.1636032";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:17;a:14:{s:9:"citazione";s:250:"Mazzilli, S., Giunta, A., Galluzzo, M., Garofalo, V., Campione, E., Di Prete, M., et al. (2019). Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA.";s:4:"data";s:10:"2019-05-14";s:2:"id";s:20:"PUBBLICAZIONE_350616";s:6:"handle";s:11:"2108/214239";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:102:"Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy";s:9:"metadata6";s:111:"Mazzilli, S; Giunta, A; Galluzzo, M; Garofalo, V; Campione, E; Di Prete, M; Orlandi, A; Ardigò, M; Bianchi, L";s:9:"metadata7";s:30:"10.23736/S0392-0488.19.06292-8";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:18;a:14:{s:9:"citazione";s:348:"Talamonti, M., D'Adamio, S., Galluccio, T., Andreani, M., Pastorino, R., Egan, C.g., et al. (2019). High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY [10.1111/jdv.15659].";s:4:"data";s:10:"2019-05-08";s:2:"id";s:20:"PUBBLICAZIONE_350621";s:6:"handle";s:11:"2108/214243";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:163:"High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab";s:9:"metadata6";s:101:"Talamonti, M; D'Adamio, S; Galluccio, T; Andreani, M; Pastorino, R; Egan, Cg; Bianchi, L; Galluzzo, M";s:9:"metadata7";s:17:"10.1111/jdv.15659";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:19;a:14:{s:9:"citazione";s:252:"Galluzzo, M., D'Adamio, S., Teoli, M., Bianchi, L., & Talamonti, M. (2019). Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. DERMATOLOGIC THERAPY, e12899 [10.1111/dth.12899].";s:4:"data";s:10:"2019-04-10";s:2:"id";s:20:"PUBBLICAZIONE_350643";s:6:"handle";s:11:"2108/214266";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:125:"Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature";s:9:"metadata6";s:60:"Galluzzo, M; D'Adamio, S; Teoli, M; Bianchi, L; Talamonti, M";s:9:"metadata7";s:17:"10.1111/dth.12899";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:20;a:14:{s:9:"citazione";s:207:"Galluzzo, M., D'Adamio, S., Chimenti, M.s., Teoli, M., Bianchi, L., & Talamonti, M. (2019). Successful treatment of psoriatic crumbly nails with ustekinumab. DERMATOLOGIC THERAPY, e12914 [10.1111/dth.12914].";s:4:"data";s:10:"2019-04-09";s:2:"id";s:20:"PUBBLICAZIONE_350777";s:6:"handle";s:11:"2108/214399";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:64:"Successful treatment of psoriatic crumbly nails with ustekinumab";s:9:"metadata6";s:74:"Galluzzo, M; D'Adamio, S; Chimenti, Ms; Teoli, M; Bianchi, L; Talamonti, M";s:9:"metadata7";s:17:"10.1111/dth.12914";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:21;a:14:{s:9:"citazione";s:244:"Chimenti, M.S., Fonti, G.L., Conigliaro, P., Hitaj, J., Triggianese, P., Teoli, M., et al. (2019). Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study. MEDICINE, 98(4), e13955.";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_364743";s:6:"handle";s:11:"2108/225722";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:29:"Settore MED/16 - Reumatologia";s:9:"metadata4";N;s:9:"metadata5";s:119:"Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study";s:9:"metadata6";s:138:"Chimenti, MS; Fonti, GL; Conigliaro, P; Hitaj, J; Triggianese, P; Teoli, M; Galluzzo, M; Talamonti, M; Kroegler, B; Greco, E; Perricone, R";s:9:"metadata7";s:27:"10.1097/MD.0000000000013955";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:22;a:14:{s:9:"citazione";s:261:"D'Adamio, S., Silvaggio, D., Lombardo, P., Bianchi, L., Talamonti, M., & Galluzzo, M. (2019). The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. EXPERT OPINION ON DRUG SAFETY, 18(11), 1031-1041 [10.1080/14740338.2019.1663168].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_358102";s:6:"handle";s:11:"2108/220183";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:72:"Biologic therapies; IL-12; IL-17; IL-23; interleukins inhibitors; safety";s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";s:1182:"Introduction: Psoriasis is a chronic inflammatory disease and affects about 10% of the world's population. Psoriasis is associated with a number of comorbidities. Biologic therapies for the treatment of moderate-severe plaque psoriasis include tumor necrosis factor α inhibitors (TNFi), and newer molecules targeting IL-12 and 23, blocking p40 subunit, or targeting subunit p19 of IL-23 and other molecules blocking IL-17A, or directed against the IL-17 receptor. Areas covered: Anti-interleukin drugs show great improvement in disease control and on the other hand are not affected by important adverse reactions of older compounds. Approach to chronic disease affected patients, in particular, and to patients with multiple comorbidities is revolutionized by novel molecules that are safer and more manageable. Expert opinion: A recent work suggests that pro-fibrogenic cytokines, IL-17, might be important player of liver damage and even in regulation of obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD) pathogenesis. Choosing to interfere with IL-23/Il-17 axis, definitely, is like acting against psoriatic march and in a parallel way against its comorbidities.";s:9:"metadata5";s:84:"The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis";s:9:"metadata6";s:77:"D'Adamio, S; Silvaggio, D; Lombardo, P; Bianchi, L; Talamonti, M; Galluzzo, M";s:9:"metadata7";s:29:"10.1080/14740338.2019.1663168";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:23;a:14:{s:9:"citazione";s:270:"Galluzzo, M., D'Adamio, S., Bianchi, L., & Talamonti, M. (2019). Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 30(1), 40-44 [10.1080/09546634.2018.1468066].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_334932";s:6:"handle";s:11:"2108/201535";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:117:"Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab";s:9:"metadata6";s:50:"Galluzzo, M; D'Adamio, S; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/09546634.2018.1468066";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:24;a:14:{s:9:"citazione";s:262:"Galluzzo, M., D'Adamio, S., Massaro, A., Piccolo, A., Bianchi, L., & Talamonti, M. (2019). Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 12, 311-321 [10.2147/CCID.S165605].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_350614";s:6:"handle";s:11:"2108/214237";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:82:"Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date";s:9:"metadata6";s:74:"Galluzzo, M; D'Adamio, S; Massaro, A; Piccolo, A; Bianchi, L; Talamonti, M";s:9:"metadata7";s:20:"10.2147/CCID.S165605";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:25;a:14:{s:9:"citazione";s:211:"Lanna, C., Mancini, M., Gaziano, R., Cannizzaro, M.v., Galluzzo, M., Talamonti, M., et al. (2019). Skin immunity and its dysregulation in psoriasis. CELL CYCLE, 18(20), 2581-2589 [10.1080/15384101.2019.1653099].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_359706";s:6:"handle";s:11:"2108/221605";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:48:"Skin immunity and its dysregulation in psoriasis";s:9:"metadata6";s:170:"Lanna, C; Mancini, M; Gaziano, R; Cannizzaro, Mv; Galluzzo, M; Talamonti, M; Rovella, V; Annicchiarico-Petruzzelli, M; Melino, G; Wang, Y; Shi, Y; Campione, E; Bianchi, L";s:9:"metadata7";s:29:"10.1080/15384101.2019.1653099";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:26;a:14:{s:9:"citazione";s:337:"Papini, M., Cusano, F., Romanelli, M., Burlando, M., Stinco, G., Girolomoni, G., et al. (2019). Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study. BRITISH JOURNAL OF DERMATOLOGY, 181(2), 413-414 [10.1111/bjd.18013].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_350635";s:6:"handle";s:11:"2108/214259";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:171:"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study";s:9:"metadata6";s:190:"Papini, M; Cusano, F; Romanelli, M; Burlando, M; Stinco, G; Girolomoni, G; Peris, K; Potenza, C; Offidani, A; Bartezaghi, M; Aloisi, E; Costanzo, A; Galluzzo, M; Supreme Study, G; Bianchi, L";s:9:"metadata7";s:17:"10.1111/bjd.18013";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:27;a:14:{s:9:"citazione";s:451:"Puviani, M., Galluzzo, M., Talamonti, M., Mazzilli, S., Campione, E., Bianchi, L., et al. (2019). Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial. INTERNATIONAL JOURNAL OF STD & AIDS, 30(2), 131-136 [10.1177/0956462418797874].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_339533";s:6:"handle";s:11:"2108/205352";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:255:"Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessmen...";s:9:"metadata6";s:109:"Puviani, M; Galluzzo, M; Talamonti, M; Mazzilli, S; Campione, E; Bianchi, L; Milani, M; Luppino, I; Micali, G";s:9:"metadata7";s:24:"10.1177/0956462418797874";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:28;a:14:{s:9:"citazione";s:233:"Rossi, A., Muscianese, M., Piraccini, B.M., Starace, M., Carlesimo, M., Mandel, V.D., et al. (2019). Italian guidelines in diagnosis and treatment of alopecia areata. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 154(6), 609-623.";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_382126";s:6:"handle";s:11:"2108/240861";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:64:"Italian guidelines in diagnosis and treatment of alopecia areata";s:9:"metadata6";s:872:"Rossi, A; Muscianese, M; Piraccini, BM; Starace, M; Carlesimo, M; Mandel, VD; Alessandrini, A; Calvieri, S; Caro, G; D'Arino, A; Federico, A; Magri, F; Pigliacelli, F; Amendolagine, G; Annunziata, MC; Arisi, MC; Astorino, S; Babino, G; Bardazzi, F; Barruscotti, S; Belloni Fortina, A; Borghi, A; Bruni, F; Caccavale, S; Calzavara-Pinton, P; Cameli, N; Cardone, M; Carugno, A; Coppola, R; Dattola, A; De Felici Del Giudice, MB; Di Cesare, A; Dika, E; Dinunno, D; D'Ovidio, R; Fabbrocini, G; Feliciani, C; Fulgione, E; Galluzzo, M; Garcovich, S; Garelli, V; Guerriero, C; Hansel, K; La Placa, M; Lacarrubba, F; Lora, V; Marinello, E; Megna, M; Micali, G; Misciali, C; Monari, P; Monfrecola, G; Neri, I; Offidani, A; Orlando, G; Papini, M; Patrizi, A; Piaserico, S; Rivetti, N; Simonetti, O; Stan, TR; Stingeni, L; Talamonti, M; Tassone, F; Villa, L; Vincenzi, C; Fortuna, MC";s:9:"metadata7";s:30:"10.23736/S0392-0488.19.06458-7";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:29;a:14:{s:9:"citazione";s:305:"Signa, S., Campione, E., Rusmini, M., Chiesa, S., Grossi, A., Omenetti, A., et al. (2019). Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL, 17(1), 38.";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_382090";s:6:"handle";s:11:"2108/240831";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:163:"Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab";s:9:"metadata6";s:184:"Signa, S; Campione, E; Rusmini, M; Chiesa, S; Grossi, A; Omenetti, A; Caorsi, R; Viglizzo, GM; Galluzzo, M; Bianchi, L; Talamonti, M; Orlandi, A; Martini, A; Ceccherini, I; Gattorno, M";s:9:"metadata7";s:25:"10.1186/s12969-019-0336-3";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:30;a:14:{s:9:"citazione";s:254:"Galluzzo, M., D'Adamio, S., Campione, E., Bianchi, L., & Talamonti, M. (2018). Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy. MOLECULAR DIAGNOSIS & THERAPY [10.1007/s40291-018-0354-8].";s:4:"data";s:10:"2018-08-03";s:2:"id";s:20:"PUBBLICAZIONE_335708";s:6:"handle";s:11:"2108/202209";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:115:"Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy";s:9:"metadata6";s:63:"Galluzzo, M; D'Adamio, S; Campione, E; Bianchi, L; Talamonti, M";s:9:"metadata7";s:25:"10.1007/s40291-018-0354-8";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:31;a:14:{s:9:"citazione";s:288:"Chimenti, M.S., Ortolan, A., Lorenzin, M., Triggianese, P., Talamonti, M., Costa, L., et al. (2018). Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. CLINICAL RHEUMATOLOGY, 37(2), 397-405.";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_338263";s:6:"handle";s:11:"2108/204340";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:29:"Settore MED/16 - Reumatologia";s:9:"metadata4";N;s:9:"metadata5";s:147:"Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study";s:9:"metadata6";s:167:"Chimenti, MS; Ortolan, A; Lorenzin, M; Triggianese, P; Talamonti, M; Costa, L; Caso, F; Favero, M; Teoli, M; Galluzzo, M; Scarpa, R; Punzi, L; Perricone, R; Ramonda, R";s:9:"metadata7";s:25:"10.1007/s10067-017-3953-6";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:32;a:14:{s:9:"citazione";s:282:"Costanzo, A., Bianchi, L., Flori, M., Malara, G., Stingeni, L., Bartezaghi, M., et al. (2018). Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. BRITISH JOURNAL OF DERMATOLOGY, 179(5), 1072-1080.";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_334926";s:6:"handle";s:11:"2108/201529";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:136:"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.";s:9:"metadata6";s:130:"Costanzo, A; Bianchi, L; Flori, M; Malara, G; Stingeni, L; Bartezaghi, M; Carraro, L; Castellino, G; Galluzzo, M; Supreme Study, G";s:9:"metadata7";s:17:"10.1111/bjd.16705";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:33;a:14:{s:9:"citazione";s:245:"Galluzzo, M., D'Adamio, S., Bianchi, L., & Talamonti, M. (2018). Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(2), 197-206 [10.1080/17425255.2018.1420162].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_324050";s:6:"handle";s:11:"2108/192235";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:83:"Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections";s:9:"metadata6";s:50:"Galluzzo, M; D'Adamio, S; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/17425255.2018.1420162";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:34;a:14:{s:9:"citazione";s:223:"Galluzzo, M., D'Adamio, S., Campione, E., Bianchi, L., & Talamonti, M. (2018). A safety evaluation of guselkumab for the treatment of psoriasis. EXPERT OPINION ON DRUG SAFETY, 17(7), 741-751 [10.1080/14740338.2018.1488963].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_334843";s:6:"handle";s:11:"2108/201465";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:64:"A safety evaluation of guselkumab for the treatment of psoriasis";s:9:"metadata6";s:63:"Galluzzo, M; D'Adamio, S; Campione, E; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/14740338.2018.1488963";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:35;a:14:{s:9:"citazione";s:279:"Galluzzo, M., D'Adamio, S., Campione, E., Mazzilli, S., Bianchi, L., & Talamonti, M. (2018). A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 29, 17-20 [10.1080/09546634.2018.1524818].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_339527";s:6:"handle";s:11:"2108/205346";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:84:"alexithymia; anti-IL17 agents; erythrodermic psoriasis; quality of life; secukinumab";s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";s:1251:"Erythrodermic psoriasis is a severe variant of psoriasis characterized by prominent erythema, affecting the entire body surface. Management of erythrodermic psoriasis is difficult, not standardized, and often ineffective. As clinical studies are lacking, reporting of clinical experience with secukinumab may help to gather insight in this field. Here, we describe the case of a 55-year-old man, with a 10-year history of moderate-to-severe plaque psoriasis. He presents a flare of erythroderma involving approximately 90% of his body surface area and a Psoriasis Area and Severity Index score of 42, with an important impact on his quality of life (DLQI score was 20.0; Skindex-29 score was 67.2). The patient presented also alexithymic features. Due to severity of clinical features and poor quality of life, the patient started secukinumab treatment; we observed a striking and rapid response to therapy with an excellent safety profile and a satisfactory compliance. Furthermore, therapy with secukinumab considerably enhanced patient's quality of life. Although further studies are needed to better understand the role of the IL-23/Th17 pathway, secukinumab can be an effective therapeutic option for patients affected by erythrodermic psoriasis.";s:9:"metadata5";s:101:"A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab";s:9:"metadata6";s:76:"Galluzzo, M; D'Adamio, S; Campione, E; Mazzilli, S; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/09546634.2018.1524818";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:36;a:14:{s:9:"citazione";s:314:"Galluzzo, M., D’Adamio, S., Pastorino, R., Angela Andreoli, A., Servoli, S., Bianchi, L., et al. (2018). Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients. EXPERT OPINION ON BIOLOGICAL THERAPY, 18(3), 229-235 [10.1080/14712598.2018.1419183].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_324048";s:6:"handle";s:11:"2108/192233";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:120:"Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients";s:9:"metadata6";s:98:"Galluzzo, M; D’Adamio, S; Pastorino, R; Angela Andreoli, A; Servoli, S; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/14712598.2018.1419183";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:37;a:14:{s:9:"citazione";s:311:"Galluzzo, M., Talamonti, M., De Simone, C., D'Adamio, S., Moretta, G., Tambone, S., et al. (2018). Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. EXPERT OPINION ON BIOLOGICAL THERAPY, 18(7), 727-735 [10.1080/14712598.2018.1481503].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_334860";s:6:"handle";s:11:"2108/201478";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:125:"Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation";s:9:"metadata6";s:125:"Galluzzo, M; Talamonti, M; De Simone, C; D'Adamio, S; Moretta, G; Tambone, S; Caldarola, G; Fargnoli, M; Peris, K; Bianchi, L";s:9:"metadata7";s:29:"10.1080/14712598.2018.1481503";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:38;a:14:{s:9:"citazione";s:323:"Talamonti, M., Galluzzo, M., Bernardini, N., Caldarola, G., Persechino, S., Cantoresi, F., et al. (2018). Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 32(10), 1737-1744.";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_334922";s:6:"handle";s:11:"2108/201525";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:134:"Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.";s:9:"metadata6";s:126:"Talamonti, M; Galluzzo, M; Bernardini, N; Caldarola, G; Persechino, S; Cantoresi, F; Egan, C; Potenza, C; Peris, K; Bianchi, L";s:9:"metadata7";s:17:"10.1111/jdv.15077";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:39;a:14:{s:9:"citazione";s:225:"Talamonti, M., Galluzzo, M., Servoli, S., D'Adamio, S., & Bianchi, L. (2017). Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. DERMATOLOGY, 232(6), 648-654 [10.1159/000453661].";s:4:"data";s:10:"2017-04-01";s:2:"id";s:20:"PUBBLICAZIONE_304025";s:6:"handle";s:11:"2108/174503";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:97:"Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.";s:9:"metadata6";s:62:"Talamonti, M; Galluzzo, M; Servoli, S; D'Adamio, S; Bianchi, L";s:9:"metadata7";s:17:"10.1159/000453661";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:40;a:14:{s:9:"citazione";s:184:"D'Adamio, S., Talamonti, M., Bianchi, L., & Galluzzo, M. (2017). Photo-recall cutaneous reaction to gemcitabine. ARCHIVE OF CLINICAL CASES, 4(4), 191-194 [10.22551/2017.17.0404.10113].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_324001";s:6:"handle";s:11:"2108/192181";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:46:"Photo-recall cutaneous reaction to gemcitabine";s:9:"metadata6";s:50:"D'Adamio, S; Talamonti, M; Bianchi, L; Galluzzo, M";s:9:"metadata7";s:27:"10.22551/2017.17.0404.10113";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:41;a:14:{s:9:"citazione";s:190:"Galluzzo, M., D’Adamio, S., Bianchi, L., & Talamonti, M. (2017). Tildrakizumab for treating psoriasis. EXPERT OPINION ON BIOLOGICAL THERAPY, 17(5), 645-657 [10.1080/14712598.2017.1304537].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_314152";s:6:"handle";s:11:"2108/183189";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:36:"Tildrakizumab for treating psoriasis";s:9:"metadata6";s:52:"Galluzzo, M; D’Adamio, S; Bianchi, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/14712598.2017.1304537";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:42;a:14:{s:9:"citazione";s:239:"Galluzzo, M., Talamonti, M., D'Adamio, S., & Bianchi, L. (2017). Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 13(6), 679-691 [10.1080/17425255.2017.1325874].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_310667";s:6:"handle";s:11:"2108/183185";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:77:"Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis";s:9:"metadata6";s:50:"Galluzzo, M; Talamonti, M; D'Adamio, S; Bianchi, L";s:9:"metadata7";s:29:"10.1080/17425255.2017.1325874";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:43;a:14:{s:9:"citazione";s:254:"Galluzzo, M., Talamonti, M., Perino, F., Servoli, S., Giordano, D., Chimenti, S., et al. (2017). Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT, 28(4), 299-303.";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_382143";s:6:"handle";s:11:"2108/240871";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:103:"Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis";s:9:"metadata6";s:98:"Galluzzo, M; Talamonti, M; Perino, F; Servoli, S; Giordano, D; Chimenti, S; De Simone, C; Peris, K";s:9:"metadata7";s:29:"10.1080/09546634.2016.1254326";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:44;a:14:{s:9:"citazione";s:207:"Talamonti, M., D'Adamio, S., Bianchi, L., & Galluzzo, M. (2017). The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature. MOLECULAR DIAGNOSIS & THERAPY [10.1007/s40291-017-0274-z].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_316124";s:6:"handle";s:11:"2108/185038";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";s:1087:"Psoriasis is a chronic inflammatory disease triggered by both genetic and environmental factors. Systemic and biologic therapies used to treat moderate-to-severe psoriasis show significant variability in efficacy, are associated with various degrees of toxicity, and, for biologic therapies, are expensive. There is a great need for non-invasive biomarkers to predict treatment outcomes of these therapies and to individualize care for patients with psoriasis. This article reviews currently recognized pharmacogenetic targets related to the treatment of chronic plaque psoriasis, in particular to biologic therapies. The use of pharmacogenetic and pharmacogenomic approaches to genetically profile patients will allow therapies to be targeted more precisely and safely to individual patients, to optimize the treatment of psoriasis, and minimize unnecessary costs. Characterizing patients with psoriasis according to common molecular mechanisms rather than by clinical phenotype may also allow more selective therapeutic agents to be targeted to genetically distinct groups of patients.";s:9:"metadata5";s:82:"The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature";s:9:"metadata6";s:50:"Talamonti, M; D'Adamio, S; Bianchi, L; Galluzzo, M";s:9:"metadata7";s:25:"10.1007/s40291-017-0274-z";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:45;a:14:{s:9:"citazione";s:319:"Talamonti, M., Galluzzo, M., Zangrilli, A., Papoutsaki, M., Egan, C., Bavetta, M., et al. (2017). HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. MOLECULAR DIAGNOSIS & THERAPY, 21(3), 295-301 [10.1007/s40291-017-0261-4].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_304051";s:6:"handle";s:11:"2108/174514";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:146:"HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.";s:9:"metadata6";s:112:"Talamonti, M; Galluzzo, M; Zangrilli, A; Papoutsaki, M; Egan, C; Bavetta, M; Tambone, S; Fargnoli, M; Bianchi, L";s:9:"metadata7";s:25:"10.1007/s40291-017-0261-4";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:46;a:14:{s:9:"citazione";s:289:"Talamonti, M., Galluzzo, M., van den Reek, J., de Jong, E., Lambert, J., Malagoli, P., et al. (2017). Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. BRITISH JOURNAL OF DERMATOLOGY, 177(2), 489-496 [10.1111/bjd.15387].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_304011";s:6:"handle";s:11:"2108/174492";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:118:"Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients.";s:9:"metadata6";s:104:"Talamonti, M; Galluzzo, M; van den Reek, J; de Jong, E; Lambert, J; Malagoli, P; Bianchi, L; Costanzo, A";s:9:"metadata7";s:17:"10.1111/bjd.15387";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:47;a:14:{s:9:"citazione";s:253:"Ventura, A., Mazzeo, M., Gaziano, R., Galluzzo, M., Bianchi, L., & Campione, E. (2017). New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. DRUG DESIGN, DEVELOPMENT AND THERAPY, 11, 2527-2535 [10.2147/DDDT.S136986].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_324059";s:6:"handle";s:11:"2108/192244";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:88:"New insight into the pathogenesis of nail psoriasis and overview of treatment strategies";s:9:"metadata6";s:71:"Ventura, A; Mazzeo, M; Gaziano, R; Galluzzo, M; Bianchi, L; Campione, E";s:9:"metadata7";s:20:"10.2147/DDDT.S136986";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:48;a:14:{s:9:"citazione";s:240:"Galluzzo, M., Andreani, M., Testi, M., Chimenti, S., & Talamonti, M. (2016). HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. MOLECULAR DIAGNOSIS & THERAPY, 20(3), 227-230.";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_382151";s:6:"handle";s:11:"2108/240877";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:115:"HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis";s:9:"metadata6";s:61:"Galluzzo, M; Andreani, M; Testi, M; Chimenti, S; Talamonti, M";s:9:"metadata7";s:25:"10.1007/s40291-016-0199-y";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:49;a:14:{s:9:"citazione";s:211:"Galluzzo, M., Boca, A.N., Botti, E., Potenza, C., Malara, G., Malagoli, P., et al. (2016). IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis. DERMATOLOGY, 232(2), 230-236.";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_330920";s:6:"handle";s:11:"2108/198117";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:89:"IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis";s:9:"metadata6";s:130:"Galluzzo, M; Boca, AN; Botti, E; Potenza, C; Malara, G; Malagoli, P; Vesa, S; Chimenti, S; Buzoianu, AD; Talamonti, M; Costanzo, A";s:9:"metadata7";s:17:"10.1159/000441719";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:50;a:14:{s:9:"citazione";s:196:"Galluzzo, M., D'Adamio, S., BIANCHI, L., & Talamonti, M. (2016). Brodalumab for the treatment of psoriasis. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 12(12), 1255-1271 [10.1080/1744666X.2016.1246957].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_294520";s:6:"handle";s:11:"2108/166148";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:41:"Brodalumab for the treatment of psoriasis";s:9:"metadata6";s:50:"Galluzzo, M; D'Adamio, S; BIANCHI, L; Talamonti, M";s:9:"metadata7";s:29:"10.1080/1744666X.2016.1246957";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:51;a:14:{s:9:"citazione";s:221:"Galluzzo, M., D'Adamio, S., Servoli, S., Bianchi, L., Chimenti, S., & Talamonti, M. (2016). Tofacitinib for the treatment of psoriasis. EXPERT OPINION ON PHARMACOTHERAPY, 17(10), 1421-1433 [10.1080/14656566.2016.1195812].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_287026";s:6:"handle";s:11:"2108/159632";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:42:"Tofacitinib for the treatment of psoriasis";s:9:"metadata6";s:75:"Galluzzo, M; D'Adamio, S; Servoli, S; Bianchi, L; Chimenti, S; Talamonti, M";s:9:"metadata7";s:29:"10.1080/14656566.2016.1195812";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:52;a:14:{s:9:"citazione";s:277:"Talamonti, M., Galluzzo, M., Chimenti, S., & Costanzo, A. (2016). Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis. Paper presented at Annual meeting of American Academy of Dermatology, 74th.";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_386252";s:6:"handle";s:11:"2108/244351";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:134:"Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis";s:9:"metadata6";s:51:"Talamonti, M; Galluzzo, M; Chimenti, S; Costanzo, A";s:9:"metadata7";s:26:"10.1016/j.jaad.2016.02.930";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:53;a:14:{s:9:"citazione";s:237:"Talamonti, M., Galluzzo, M., Chimenti, S., & Costanzo, A. (2016). HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74(2), 374-375.";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_382157";s:6:"handle";s:11:"2108/240883";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:106:"HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up";s:9:"metadata6";s:51:"Talamonti, M; Galluzzo, M; Chimenti, S; Costanzo, A";s:9:"metadata7";s:26:"10.1016/j.jaad.2015.08.055";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:54;a:14:{s:9:"citazione";s:339:"Chimenti, M.S., Talamonti, M., Novelli, L., Teoli, M., Galluzzo, M., Triggianese, P., et al. (2015). Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature. JOURNAL OF DERMATOLOGICAL CASE REPORTS, 9(3), 71-75 [10.3315/jdcr.2015.1207].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_280804";s:6:"handle";s:11:"2108/155229";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:29:"Settore MED/16 - Reumatologia";s:9:"metadata4";N;s:9:"metadata5";s:159:"Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature";s:9:"metadata6";s:91:"Chimenti, MS; Talamonti, M; Novelli, L; Teoli, M; Galluzzo, M; Triggianese, P; Perricone, R";s:9:"metadata7";s:22:"10.3315/jdcr.2015.1207";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:55;a:14:{s:9:"citazione";s:215:"Galluzzo, M., Talamonti, M., Di Stefani, A., & Chimenti, S. (2015). Linear psoriasis following the typical distribution of the sciatic nerve. JOURNAL OF DERMATOLOGICAL CASE REPORTS, 9, 6-11 [10.3315/jdcr.2015.1189].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_372522";s:6:"handle";s:11:"2108/232348";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:72:"Linear psoriasis following the typical distribution of the sciatic nerve";s:9:"metadata6";s:53:"Galluzzo, M; Talamonti, M; Di Stefani, A; Chimenti, S";s:9:"metadata7";s:22:"10.3315/jdcr.2015.1189";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:56;a:14:{s:9:"citazione";s:290:"Talamonti, M., Galluzzo, M., Botti, E., Costanzo, A., & Chimenti, S. (2015). HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients. Paper presented at ANNUAL MEETING OF AmERICAN AcadEMY OF DermatolOGY.";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_386194";s:6:"handle";s:11:"2108/244353";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:141:"HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients";s:9:"metadata6";s:61:"Talamonti, M; Galluzzo, M; Botti, E; Costanzo, A; Chimenti, S";s:9:"metadata7";s:26:"10.1016/j.jaad.2015.02.952";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:57;a:14:{s:9:"citazione";s:254:"Talamonti, M., Galluzzo, M., Bianchi, L., Boca, A.N., Costanzo, A., & Chimenti, S. (2014). What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice. DERMATOLOGY, 229(4), 324-332 [10.1159/000365077].";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_238443";s:6:"handle";s:11:"2108/119597";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:112:"What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice";s:9:"metadata6";s:73:"Talamonti, M; Galluzzo, M; Bianchi, L; Boca, AN; Costanzo, A; Chimenti, S";s:9:"metadata7";s:17:"10.1159/000365077";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:58;a:14:{s:9:"citazione";s:375:"Talamonti, M., Galluzzo, M., Botti, E., Chimenti, S., & Costanzo, A. (2014). Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment. Paper presented at 7thInternational Congress of Psoriasis: from Gene to Clinic The Queen Elizabeth II Conference Centre, London, U.K. 11th-13th December 2014.";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_386203";s:6:"handle";s:11:"2108/244296";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:138:"Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment";s:9:"metadata6";s:61:"Talamonti, M; Galluzzo, M; Botti, E; Chimenti, S; Costanzo, A";s:9:"metadata7";s:17:"10.1111/bjd.13488";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:59;a:14:{s:9:"citazione";s:306:"Talamonti, M., Botti, E., Galluzzo, M., Teoli, M., Spallone, G., Bavetta, M., et al. (2013). Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. BRITISH JOURNAL OF DERMATOLOGY, 169(2), 458-463.";s:4:"data";s:7:"2013-08";s:2:"id";s:20:"PUBBLICAZIONE_330934";s:6:"handle";s:11:"2108/198131";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:163:"Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab";s:9:"metadata6";s:96:"Talamonti, M; Botti, E; Galluzzo, M; Teoli, M; Spallone, G; Bavetta, M; Chimenti, S; Costanzo, A";s:9:"metadata7";s:17:"10.1111/bjd.12331";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:60;a:14:{s:9:"citazione";s:411:"Boca, A., Talamonti, M., Galluzzo, M., Botti, E., Buzoianu, A., & Costanzo., A. (2013). Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom. Paper presented at 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom.";s:4:"data";s:7:"2013-05";s:2:"id";s:20:"PUBBLICAZIONE_386209";s:6:"handle";s:11:"2108/244298";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:196:"Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom";s:9:"metadata6";s:71:"Boca, A; Talamonti, M; Galluzzo, M; Botti, E; Buzoianu, A; Costanzo., A";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:61;a:14:{s:9:"citazione";s:248:"Boca, A.N., Talamonti, M., Galluzzo, M., Botti, E., Buzoianu, A.D., & Costanzo, A. (2013). Genetic variations in IL6 and IL12B as protective markers for psoriasis. Paper presented at International Investigative Dermatology 8-11 May 2013, Edinburgh.";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_404537";s:6:"handle";s:11:"2108/260600";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:71:"Genetic variations in IL6 and IL12B as protective markers for psoriasis";s:9:"metadata6";s:72:"Boca, AN; Talamonti, M; Galluzzo, M; Botti, E; Buzoianu, AD; Costanzo, A";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:62;a:14:{s:9:"citazione";s:202:"Boca, A.N., Talamonti, M., Galluzzo, M., Botti, E., Vesa, T.C., Chimenti, S., et al. (2013). Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. IMMUNOLOGY LETTERS, 156(1-2), 127-131.";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_330932";s:6:"handle";s:11:"2108/198129";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:43:"Settore MED/35 - Malattie Cutanee e Veneree";s:9:"metadata4";N;s:9:"metadata5";s:69:"Genetic variations in IL6 and IL12B decreasing the risk for psoriasis";s:9:"metadata6";s:95:"Boca, AN; Talamonti, M; Galluzzo, M; Botti, E; Vesa, TC; Chimenti, S; Buzoianu, AD; Costanzo, A";s:9:"metadata7";s:27:"10.1016/j.imlet.2013.09.028";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:63;a:14:{s:9:"citazione";s:253:"Di Stefani, A., Galluzzo, M., Talamonti, M., Chiricozzi, A., Costanzo, A., & Chimenti, S. (2013). Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. JOURNAL OF DERMATOLOGICAL CASE REPORTS, 7(1), 5-9 [10.3315/jdcr.2013.1127].";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_382178";s:6:"handle";s:11:"2108/240906";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:78:"Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris";s:9:"metadata6";s:81:"Di Stefani, A; Galluzzo, M; Talamonti, M; Chiricozzi, A; Costanzo, A; Chimenti, S";s:9:"metadata7";s:22:"10.3315/jdcr.2013.1127";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:64;a:14:{s:9:"citazione";s:244:"Saraceno, R., Talamonti, M., Galluzzo, M., Chiricozzi, A., Costanzo, A., & Chimenti, S. (2013). Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases. CASE REPORTS IN DERMATOLOGY, 5(3), 254-258.";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_382172";s:6:"handle";s:11:"2108/240900";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:103:"Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases";s:9:"metadata6";s:79:"Saraceno, R; Talamonti, M; Galluzzo, M; Chiricozzi, A; Costanzo, A; Chimenti, S";s:9:"metadata7";s:17:"10.1159/000348645";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:65;a:14:{s:9:"citazione";s:273:"Talamonti, M., Galluzzo, M., Botti, E., Pavlidis, A., Spallone, G., Chimenti, S., et al. (2013). Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients. CLINICAL DRUG INVESTIGATION, 33(SUPPL.2).";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_382187";s:6:"handle";s:11:"2108/240912";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:133:"Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients";s:9:"metadata6";s:87:"Talamonti, M; Galluzzo, M; Botti, E; Pavlidis, A; Spallone, G; Chimenti, S; Costanzo, A";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:66;a:14:{s:9:"citazione";s:337:"Botti, E., Talamonti, M., Spallone, G., Galluzzo, M., Bavetta, M., Teoli, M., et al. (2012). Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis. Paper presented at Abstracts of the 42nd Annual ESDR (European Society for Dermatological Research) Meeting. September 7-10, 2012. Venice, Italy.";s:4:"data";s:7:"2012-09";s:2:"id";s:20:"PUBBLICAZIONE_386218";s:6:"handle";s:11:"2108/244306";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:97:"Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis";s:9:"metadata6";s:95:"Botti, E; Talamonti, M; Spallone, G; Galluzzo, M; Bavetta, M; Teoli, M; Pinetti, V; Costanzo, A";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:67;a:14:{s:9:"citazione";s:227:"Talamonti, M., Galluzzo, M., Chiricozzi, A., Teoli, M., Bavetta, M., Costanzo, A., et al. (2012). Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome. JOURNAL OF DRUGS IN DERMATOLOGY, 11(8), 1000-1002.";s:4:"data";s:4:"2012";s:2:"id";s:20:"PUBBLICAZIONE_382210";s:6:"handle";s:11:"2108/240934";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:77:"Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome";s:9:"metadata6";s:88:"Talamonti, M; Galluzzo, M; Chiricozzi, A; Teoli, M; Bavetta, M; Costanzo, A; Chimenti, S";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:68;a:14:{s:9:"citazione";s:292:"Talamonti, M., Galluzzo, M., Teoli, M., Bavetta, M., Chimenti, S., & Costanzo, A. (2011). Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis. Paper presented at Psoriasis: from Gene to Clinic 6th International Congress, 1-3 December 2011.";s:4:"data";s:4:"2011";s:2:"id";s:20:"PUBBLICAZIONE_386220";s:6:"handle";s:11:"2108/244308";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/35";s:9:"metadata4";N;s:9:"metadata5";s:104:"Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis";s:9:"metadata6";s:73:"Talamonti, M; Galluzzo, M; Teoli, M; Bavetta, M; Chimenti, S; Costanzo, A";s:9:"metadata7";s:32:"10.1111/j.1365-2133.2011.10671.x";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}}" } ["meta_keywords"]=> array(1) { [0]=> string(1) "," } ["reserved"]=> array(1) { [0]=> string(1) "0" } ["auth_ip"]=> array(1) { [0]=> string(1) "0" } } ["_fieldBoosts":protected]=> array(6) { ["content_id"]=> bool(false) ["content_title"]=> bool(false) ["description"]=> bool(false) ["meta_keywords"]=> bool(false) ["reserved"]=> bool(false) ["auth_ip"]=> bool(false) } } }